1887
Rapid communication Open Access
Like 0

Abstract

In August 2021, a man who has sex with men was diagnosed with HIV-1 infection despite using event-driven pre-exposure prophylaxis for over 2 years with self-reported excellent adherence. Sequencing identified resistance-associated mutations (RAM) M184V and K65R, conferring resistance to emtricitabine and tenofovir, and RAM V108I and E138A. Background RAM prevalence was two of 164 (1.2%) new HIV diagnoses in Amsterdam (2017–19). We reiterate the need for frequent HIV testing among PrEP users and additional testing in case of symptoms.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.14.2200275
2022-04-07
2022-05-23
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2022.27.14.2200275
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/14/eurosurv-27-14-1.html?itemId=/content/10.2807/1560-7917.ES.2022.27.14.2200275&mimeType=html&fmt=ahah

References

  1. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973-83.  https://doi.org/10.1097/QAD.0000000000001145  PMID: 27149090 
  2. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237-46.  https://doi.org/10.1056/NEJMoa1506273  PMID: 26624850 
  3. Cohen SE, Sachdev D, Lee SA, Scheer S, Bacon O, Chen MJ, et al. Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. Lancet HIV. 2018;S2352-3018(18)30288-1. PMID: 30503324 
  4. Colby DJ, Kroon E, Sacdalan C, Gandhi M, Grant RM, Phanuphak P, et al. Acquisition of multidrug-resistant human immunodeficiency virus type 1 infection in a patient taking preexposure prophylaxis. Clin Infect Dis. 2018;67(6):962-4.  https://doi.org/10.1093/cid/ciy321  PMID: 29961859 
  5. Knox DC, Anderson PL, Harrigan PR, Tan DH. Multidrug-resistant HIV-1 Infection despite preexposure prophylaxis. N Engl J Med. 2017;376(5):501-2.  https://doi.org/10.1056/NEJMc1611639  PMID: 28146652 
  6. Markowitz M, Grossman H, Anderson PL, Grant R, Gandhi M, Horng H, et al. newly acquired infection with multidrug-resistant HIV-1 in a patient adherent to preexposure prophylaxis. J Acquir Immune Defic Syndr. 2017;76(4):e104-6.  https://doi.org/10.1097/QAI.0000000000001534  PMID: 29076941 
  7. Thaden JT, Gandhi M, Okochi H, Hurt CB, McKellar MS. Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination. AIDS. 2018;32(9):F1-4.  https://doi.org/10.1097/QAD.0000000000001825  PMID: 29683856 
  8. Hoornenborg E, Prins M, Achterbergh RCA, Woittiez LR, Cornelissen M, Jurriaans S, et al. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. Lancet HIV. 2017;4(11):e522-8.  https://doi.org/10.1016/S2352-3018(17)30132-7  PMID: 28919303 
  9. Urbanus AT, Blom C, Zantkuijl P, David S. PrEP-dossier: Pre-Expositie Profylaxe voor hiv-negatieven in Nederland. [PrEP-dossier: Pre-exposure prophylaxis for HIV-negative individuals in the Netherlands]. Bilthoven: Rijksinstituut voor Volksgezondheid en Milieu; 2017. Dutch. Available from: https://rivm.openrepository.com/handle/10029/620902
  10. Hoornenborg E, Coyer L, Achterbergh RCA, Matser A, Schim van der Loeff MF, Boyd A, et al. Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study. Lancet HIV. 2019;6(7):e447-55.  https://doi.org/10.1016/S2352-3018(19)30136-5  PMID: 31178284 
  11. The Dutch Association of HIV-treating physicians (NVHB). Richtlijn HIV. [HIV treatment guidelines]. NVHB; 2019. Dutch. Available from: https://www.hiv-monitoring.nl/en/resources/hiv-treatment-guidelines
  12. Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J Infect Dis. 2015;211(8):1211-8.  https://doi.org/10.1093/infdis/jiu677  PMID: 25587020 
  13. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Washington, DC: Department of Health and Human Services; 2022. Available from: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines
  14. Zheng JH, Rower C, McAllister K, Castillo-Mancilla J, Klein B, Meditz A, et al. Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal. 2016;122:16-20.  https://doi.org/10.1016/j.jpba.2016.01.038  PMID: 26829517 
  15. Jongen VW, Hoornenborg E, van den Elshout MA, Boyd A, Zimmermann HM, Coyer L, et al. Adherence to event-driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3-monthly questionnaires and intracellular TFV-DP. J Int AIDS Soc. 2021;24(5):e25708.  https://doi.org/10.1002/jia2.25708  PMID: 33973373 
  16. Ambrosioni J, Petit E, Liegeon G, Laguno M, Miró JM. Primary HIV-1 infection in users of pre-exposure prophylaxis. Lancet HIV. 2021;8(3):e166-74.  https://doi.org/10.1016/S2352-3018(20)30271-X  PMID: 33316212 
  17. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019;393(10189):2428-38.  https://doi.org/10.1016/S0140-6736(19)30418-0  PMID: 31056293 
/content/10.2807/1560-7917.ES.2022.27.14.2200275
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error